President And Ceo
CurrentTVAX Immunotherapy® is a novel autologous vaccine-enhanced adoptive T cell immunotherapy for cancer. This proprietary immunotherapy platform has demonstrated efficacy against several cancers with low toxicity, potentially offering a paradigm shift in the systemic treatment of cancer. Activated “killer” T cells have shown the ability to effectively treat.